Free Trial
NASDAQ:NKTX

Nkarta (NKTX) Stock Price, News & Analysis

$6.53
-0.20 (-2.97%)
(As of 05/21/2024 ET)
Today's Range
$6.39
$6.74
50-Day Range
$6.25
$13.10
52-Week Range
$1.28
$16.24
Volume
334,535 shs
Average Volume
1.69 million shs
Market Capitalization
$322.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.83

Nkarta MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
176.9% Upside
$17.83 Price Target
Short Interest
Bearish
14.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.08mentions of Nkarta in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$20 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.27) to ($2.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.64 out of 5 stars

Medical Sector

439th out of 921 stocks

Pharmaceutical Preparations Industry

191st out of 417 stocks

NKTX stock logo

About Nkarta Stock (NASDAQ:NKTX)

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

NKTX Stock Price History

NKTX Stock News Headlines

Nkarta Inc Ordinary Shares
Nkarta (NASDAQ:NKTX) PT Lowered to $15.00
NKTX Stock Earnings: Nkarta Beats EPS for Q1 2024
TD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)
See More Headlines
Receive NKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
5/21/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NKTX
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.83
High Stock Price Target
$25.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+178.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-117,500,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.56 per share

Miscellaneous

Free Float
46,649,000
Market Cap
$316.78 million
Optionable
Optionable
Beta
0.88
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Paul J. HastingsMr. Paul J. Hastings (Age 64)
    CEO, President & Director
    Comp: $938.41k
  • Dr. Alicia J. Hager (Age 54)
    Chief Legal Officer & Corporate Secretary
    Comp: $590.94k
  • Ms. Alyssa Levin C.A. (Age 39)
    CPA, Chief Financial & Business Officer and Principal Accounting Officer
  • Dr. Ralph Brandenberger Ph.D. (Age 55)
    Chief Technical Officer
  • Dr. James Trager Ph.D. (Age 61)
    Chief Scientific Officer
  • Mr. Greg Mann
    Vice President of Public Affairs and Investor Relations
  • Dr. David R. Shook M.D. (Age 46)
    Chief Medical Officer

NKTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Nkarta stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NKTX shares.
View NKTX analyst ratings
or view top-rated stocks.

What is Nkarta's stock price target for 2024?

5 analysts have issued 1-year price objectives for Nkarta's stock. Their NKTX share price targets range from $13.00 to $25.00. On average, they expect the company's stock price to reach $17.83 in the next year. This suggests a possible upside of 176.9% from the stock's current price.
View analysts price targets for NKTX
or view top-rated stocks among Wall Street analysts.

How have NKTX shares performed in 2024?

Nkarta's stock was trading at $6.60 at the start of the year. Since then, NKTX stock has decreased by 2.4% and is now trading at $6.44.
View the best growth stocks for 2024 here
.

When is Nkarta's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our NKTX earnings forecast
.

How were Nkarta's earnings last quarter?

Nkarta, Inc. (NASDAQ:NKTX) issued its quarterly earnings results on Thursday, March, 21st. The company reported ($0.57) earnings per share for the quarter, topping analysts' consensus estimates of ($0.62) by $0.05.

What other stocks do shareholders of Nkarta own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Block (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND), Citigroup (C), Salesforce (CRM), CVS Health (CVS) and DraftKings (DKNG).

When did Nkarta IPO?

Nkarta (NKTX) raised $150 million in an IPO on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO.

Who are Nkarta's major shareholders?

Nkarta's stock is owned by a number of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (21.86%), SR One Capital Management LP (6.74%), Vanguard Group Inc. (3.98%), Wasatch Advisors LP (2.36%), Janus Henderson Group PLC (1.70%) and Susquehanna Fundamental Investments LLC (0.15%). Insiders that own company stock include David Shook, James Trager, Kanya Rajangam, Nadir Mahmood, Paul J Hastings, Paul J Hastings, Ra Capital Management, LP, Ralph Brandenberger and Simeon George.
View institutional ownership trends
.

How do I buy shares of Nkarta?

Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NKTX) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners